Request Demo
Last update 06 Dec 2025
LAM-003
Last update 06 Dec 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms LAM 003 |
Target |
Action inhibitors |
Mechanism HSP90B inhibitors(Heat shock protein HSP 90-beta inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with LAM-003NCT03426605
A Phase 1 Dose-Escalation Study of LAM-003 in Patients With Acute Myeloid Leukemia
100 Clinical Results associated with LAM-003
Login to view more data
100 Translational Medicine associated with LAM-003
Login to view more data
100 Patents (Medical) associated with LAM-003
Login to view more data
1
Literatures (Medical) associated with LAM-00326 Nov 2019Blood advancesQ2 · MEDICINE
LAM-003, a new drug for treatment of tyrosine kinase inhibitor–resistant FLT3-ITD–positive AML
Q2 · MEDICINE
Article
Author: Halene, Stephanie ; Zhang, Xuan ; Landrette, Sean ; Rothberg, Jonathan ; Grotzke, Jeff E. ; Beckett, Paul ; Young, Peter R. ; Andreeff, Michael ; Hernandez, Marylens ; Xu, Tian ; Gayle, Sophia ; Carter, Bing Z. ; Lichenstein, Henri ; Beeharry, Neil
Key Points:
The heat shock protein 90 inhibitor LAM-003 displays potent in vitro and in vivo activity as a single agent and combined with venetoclax. LAM-003 retains antileukemic activity against AML cells rendered resistant to FLT3 kinase inhibitors by mutation or stromal signaling.
100 Deals associated with LAM-003
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Myeloid Leukemia | Phase 1 | United States | 16 Jan 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 17 | (LAM-003 200 mg QD) | qahhgetezb = azsektktim suhuqsvfxy (xaualajxhs, ciqskayler - dhrgjlphch) View more | - | 03 May 2024 | ||
(LAM-003 300 mg QD) | qahhgetezb = ypupxqsppu suhuqsvfxy (xaualajxhs, hfjxmekunr - qvwegtloal) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free